https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma

Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared to intravenous administration, enhancing patient outcomes.

administrator

Related Articles